The real-world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review.

This study examined the change in weight at 6 months of naltrexone/bupropion (NB), a combination pharmacological therapy for weight management, in real-world practice in Canada. The study was conducted through an observational, retrospective, single-arm chart review of adult patients who attended the Wharton Medical Clinic in Ontario, Canada, between 2018 and 2021. The patients had a body mass index ≥30 or ≥27 kg/m with at least one weight-related comorbidity.

Healthcare utilization associated with obesity management in Ontario, Canada.

This study aimed to describe the characteristics, healthcare resources utilized and costs incurred by adults receiving publicly funded obesity care in Ontario, Canada. People living with obesity who first visited Wharton Medical Clinic, a weight and diabetes management clinic in Ontario, between 2015 and 2018 were identified. Pseudoanonymized data were linked to administrative databases to understand healthcare utilization and costs borne by the public payer over 3 years.

Grazing and food addiction: Associations between varied patterns of overconsumption and addictive-like eating.

Background: Food addiction (FA) research has primarily concentrated on binge eating as a symptom of this condition. However, FA may encompass various overeating behaviours, including compulsive grazing - the repetitive consumption of small amounts of food with loss of control. This study extends our previous research by including a clinical sample to investigate whether compulsive grazing exists in a population with higher prevalence and severity of FA.

Tirzepatide for Obesity Treatment and Diabetes Prevention.

Background: Obesity is chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here, we report the 3-year safety outcomes with tirzepatide and its efficacy in reducing weight and delaying progression to type 2 diabetes in persons with both obesity and prediabetes.

Analysis of the sensitivity of high-grade squamous intraepithelial lesion Pap diagnosis and interobserver variability with the Hologic Genius Digital Diagnostics System.

Background: Artificial intelligence (AI)-based systems are transforming cytopathology practice. The aim of this study was to evaluate the sensitivity of high-grade squamous intraepithelial lesion (HSIL) Papanicolaou (Pap) diagnosis assisted by the Hologic Genius Digital Diagnostics System (GDDS).

Methods: A validation study was performed with 890 ThinPrep Pap tests with the GDDS independently.